Breast cancer, hormone therapy, adverse effects and adherence
breast cancer, Hormone-dependent breast cancer, cancer, pain, anti-Aromatase/GnRH, tumors
RECURRENCE, BREAST CANCER, CANCER, TUMORS, ADVERSE DRUG REACTIONS
With 58,459 new cases yearly in France, breast cancer remains the most common cancer in women [Hormone-dependent breast cancer can relapse long after treatment has ended. Approximately 80% of patients have hormone receptor-positive (HR+) tumors [To reduce the risk of recurrence in women with HR + breast cancer, hormone therapy is prescribed for at least 5 years. Tamoxifen has become the gold standard of treatment before menopause while aromatase inhibitors have become established after menopause. Randomized trials and meta-analyses have shown that these hormone therapies lead to a gain in relapse-free and overall survivals [Hormone therapy is responsible for adverse drug reactions (ADRs) that usually occur between one and three months after the start of treatment. These ADRs are related to the absence of estrogen impregnation and vary according to the type of medication used (Tamoxifen® or anti-Aromatase/GnRH analogues) and to the patient’s menopausal status. They are related and intertwined with the menopausal effects in women, whatever the menopause was before diagnosis or occurred during chemotherapy.The most commonly described ADRs are joint pain [